Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:neurodegenerative_diseases
|
| gptkbp:affects |
gptkb:Heart
gptkb:computer kidneys gastrointestinal tract |
| gptkbp:associated_with |
gptkb:familial_amyloid_cardiomyopathy
gptkb:familial_amyloid_polyneuropathy aging |
| gptkbp:caused_by |
transthyretin protein misfolding
|
| gptkbp:clinical_trial |
ongoing studies
phase 1 trials phase 2 trials phase 3 trials |
| gptkbp:diagnosis |
genetic testing
biopsy |
| gptkbp:first_described_by |
gptkb:1952
|
| gptkbp:genetic_studies |
TTR gene mutation
|
| gptkbp:historical_significance |
collaboration among researchers
advancements in treatment options greater public awareness increased research interest improved diagnostic techniques |
| https://www.w3.org/2000/01/rdf-schema#label |
Transthyretin amyloidosis
|
| gptkbp:prevalence |
rare disease
|
| gptkbp:public_awareness |
patient education
community support research funding advocacy groups fundraising efforts |
| gptkbp:research_focus |
treatment efficacy
diagnostic methods amyloid fibril formation |
| gptkbp:risk_factor |
family history
certain ethnic groups |
| gptkbp:symptoms |
heart failure
peripheral neuropathy carpal tunnel syndrome |
| gptkbp:treatment |
gptkb:diflunisal
gptkb:tafamidis improved quality of life reduced symptoms liver transplantation slowed disease progression increased survival rates |
| gptkbp:bfsParent |
gptkb:NTLA-2001
gptkb:NTLA-2002 |
| gptkbp:bfsLayer |
5
|